Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)
ID: 357815Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357815

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-326.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access program under funding opportunity number PAR-25-326. This initiative aims to facilitate access to contract research organizations and subject matter experts to support nonclinical development activities for gene-based therapies targeting ultra-rare neurological and neuromuscular diseases. The program emphasizes the urgency of developing tailored therapies due to the critical nature of these conditions and the lack of existing commercial therapeutic options, encouraging proposals that demonstrate proof of concept data for defined patient populations. Applications are accepted on a rolling basis, with a close date of January 31, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. Additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-326.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-326-Full-Announcement.html
    PAR-25-326.html
    The National Institutes of Health (NIH) is inviting applications for the Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access program under the funding opportunity number PAR-25-326. This initiative aims to facilitate access to contract research organizations and subject matter experts to support nonclinical development activities for gene-based therapies targeting ultra-rare neurological and neuromuscular diseases. The program encourages proposals that demonstrate proof of concept data for a defined patient population, addressing significant unmet medical needs. Key activities include planning and limited nonclinical studies that may lead to an Investigational New Drug (IND) application with the FDA. Applications are accepted on a rolling basis with specific submission deadlines, focused on enhancing access to URGenT resources, developing product plans, and ensuring regulatory compliance. The program does not provide direct funding but offers support through access to specialized resources to aid in the advancement of therapeutics for ultra-rare diseases. This NOFO emphasizes the urgency of developing tailored therapies due to the critical nature of these conditions and the lack of existing commercial therapeutic options.
    Similar Opportunities
    Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute of Neurological Disorders and Stroke (NINDS), has announced a funding opportunity titled "Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access" (X01), aimed at facilitating research in gene-based therapies for ultra-rare neurological disorders affecting fewer than 6,000 individuals in the U.S. This initiative provides investigators with access to contract research organizations (CROs) and subject matter experts to assist in planning, manufacturing, and nonclinical therapeutic development, specifically for the preparation of Investigational New Drug (IND) applications without involving clinical trials. The program emphasizes collaboration and strategic planning to address the unmet medical needs of patients with ultra-rare diseases, encouraging multidisciplinary project teams to outline development plans and regulatory considerations. Interested applicants must submit their proposals by January 24, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. Additional information can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-028.html.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." This initiative aims to support the clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders, focusing on establishing their clinical sensitivity and specificity in accordance with FDA guidelines. The program is particularly significant as it seeks to enhance public health outcomes by facilitating the implementation of validated biomarkers in clinical settings, thereby addressing critical healthcare needs in these areas. Interested applicants should note that the application period opens on January 21, 2025, and closes on June 22, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-055.html.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated efficacy clinical trials through the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) program. This initiative aims to support clinical studies that evaluate drugs, biologics, devices, and various interventions targeting neurological disorders, requiring a phased approach where UG3 planning must precede UH3 execution. The trials must be well-designed with robust scientific rationale and diverse participant inclusion, emphasizing collaboration with patient advocacy groups and national networks. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of January 9, 2025, and no cost-sharing or matching requirements. For inquiries, contact the NIH OER Webmaster at grantsinfo@nih.gov.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that align with NINDS's mission, focusing on innovative approaches to evaluate drugs, devices, and interventions for neurological disorders. The funding is structured as a cooperative agreement with a maximum support period of five years, where the UG3 phase lasts up to two years, followed by a potential transition to the UH3 phase for executing clinical trials. Interested applicants should note that the application process opens on January 10, 2025, with a submission deadline of March 11, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.
    Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders through a phased grant mechanism (R61/R33). This funding opportunity aims to enhance the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and improve clinical care decisions. The initiative emphasizes the importance of multidisciplinary collaboration and requires applicants to validate biomarkers in a phased approach, with the R61 phase focusing on proof of concept studies and the R33 phase on preliminary clinical validation. Interested applicants should note that the application deadline is January 7, 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html.